- Morgan Stanley lifts price target on Lilly to a Street-high
- Drugmaker now among 10 most valuable US companies after rally
Eli Lilly & Co.’s relentless stock records have Morgan Stanley analysts musing whether it will become the first US company outside of the Magnificent Seven to reach a market value of $1 trillion.
The analysts lifted their price target on the weight-loss drugmaker to the highest on Wall Street on Friday, to a level that would take the market capitalization to about $900 billion, according to Bloomberg calculations.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.